Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Ascendis Pharma A/S

Ascendis Pharma A/S (ASND) Stock Overview

Explore Ascendis Pharma A/S’s financial performance, market position, analyst ratings, and future outlook.

ASND●NASDAQ
HealthcareBiotechnology
$259.28
$2.69(1.05%)
U.S. Market opens in 1h 57m

Ascendis Pharma A/S (ASND)

Meyka AI Score

Z

Key Financials

Market Cap17.1B
P/E Ratio19.18
EPS (TTM)$-2.42
ROE1.90%
Fundamental Analysis

AI Price Forecasts

1 Month$258.20
3 Months$270.05
1 Year Target$242.24

ASND Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Ascendis Pharma A/S (NASDAQ: ASND) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Ascendis Pharma A/S's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ASND on the NASDAQ shows an RSI of 64.51, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $242.24 for the NASDAQ listing.

Key metrics behind Ascendis Pharma A/S's NASDAQ-traded stock include a P/E ratio of 19.18 and a market capitalization of 17.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ASND on the NASDAQ.

Price Performance (NASDAQ: ASND)

1-Day Change
1.05%
5-Day Change
2.30%
1-Month Change
13.11%
3-Month Change
1.85%
6-Month Change
8.64%
Year-to-Date (YTD) Change
21.59%
1-Year Change
28.89%
3-Year Change
189.93%
5-Year Change
67.28%
All-Time (Max) Change
1276.95%

Contact Information

https://ascendispharma.com
45 70 22 22 44
Tuborg Boulevard 12, Hellerup, CR, 2900

Company Facts

11,890 Employees
IPO DateJan 28, 2015
CountryDK
Actively Trading

Frequently Asked Questions